Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 14.2 NOK 1% Market Closed
Market Cap: 725.2m NOK
Have any thoughts about
Arcticzymes Technologies ASA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

123.5
Current
68.9
Median
4.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
123.5
=
Enterprise Value
555.3m NOK
/
EBITDA
4.5m NOK
All Countries
Close
Market Cap EV/EBITDA
NO
Arcticzymes Technologies ASA
OSE:AZT
720.1m NOK 123.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 529.4
US
Abbvie Inc
NYSE:ABBV
318.3B USD 15.5
US
Amgen Inc
NASDAQ:AMGN
139B USD 15.8
US
Gilead Sciences Inc
NASDAQ:GILD
113.7B USD 10
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.7B USD 21.3
US
Epizyme Inc
F:EPE
94.1B EUR -512.3
AU
CSL Ltd
ASX:CSL
138.5B AUD 20.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD 15.4
US
Seagen Inc
F:SGT
39.3B EUR -58.5
NL
argenx SE
XBRU:ARGX
36.6B EUR -159.4
EBITDA Growth EV/EBITDA to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBITDA: 31.7
123.5
4%
30.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 529.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
15.8
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
13%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.3 N/A N/A
AU
CSL Ltd
ASX:CSL
20.2
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -159.4 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
183.3
2-Years Forward
EV/EBITDA
52.4
3-Years Forward
EV/EBITDA
22